{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-22-000579","form_type":"8-K","ticker":"LCTC","cik":"0001493137","company_name":"Lifeloc Technologies, Inc","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.899965+00:00","generated_at":"2026-06-25T18:09:01.749936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lifeloc Q1 2022 net loss $145K vs profit $403K in Q1 2021, revenue up 19% to $2.161M","bullets":["Net loss of $145K ($0.06 diluted EPS) vs. net profit of $403K ($0.16 diluted EPS) in Q1 2021, which included a $465K PPP loan forgiveness gain.","Revenue $2.161M, up 19% YoY, driven by demand recovery and new product adoption.","R&D investment increased to develop SpinDx drug testing platform; expects initial SpinDx sales this year.","New LX9 and LT7 devices driving strong sales growth; L-series products gaining market traction."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-22-000579","json":"https://secwatch.observer/filing/0001079973-22-000579.json","markdown":"https://secwatch.observer/filing/0001079973-22-000579.md","text":"https://secwatch.observer/filing/0001079973-22-000579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493137/000107997322000579/0001079973-22-000579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493137/000107997322000579/lclc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:09:01.749936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}